Clinical evaluation of microbicide formulations

Antiviral Research

Volumn 88, Issue SUPPL., 2010, Pages

  Morrow, Kathleen M ^a   Hendrix, Craig ^b  

^a BROWN UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acceptability; Clinical evaluation; HIV prevention; Microbicide development; Pharmacokinetics; Toxicity

Indexed keywords

ENEMA; MICROBICIDE;

CLINICAL EVALUATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIBIDO DISORDER; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SEMINAL PLASMA; TOXICOKINETICS; VAGINA RING; VAGINA SECRETION;

ADMINISTRATION, INTRAVAGINAL; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS AS TOPIC; DOSAGE FORMS; DRUG AND NARCOTIC CONTROL; DRUG INTERACTIONS; FEMALE; HIV; HIV INFECTIONS; HOST-PATHOGEN INTERACTIONS; HUMANS; MALE; SEXUAL BEHAVIOR; VAGINA;

EID: 78649407259     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.09.008     Document Type: Review

References (79)

1. Barnhart K., Kulp J.L., Rosen M., Shera D.M. A randomized trial to determine the distribution of four topical gel formulations in the human vagina. Contraception 2009, 79:297-303.
2. Barnhart K.T., Pretorius E.S., Shera D.M., Shabbout M., Shaunik A. The optimal analysis of MRI data to quantify the distribution of a microbicide. Contraception 2006, 73:82-87.
3. Barnhart K.T., Pretorius E.S., Timbers K., Shera D., Shabbout M., Malamud D. In vivo distribution of a vaginal gel: MRI evaluation of the effects of gel volume, time and simulated intercourse. Contraception 2004, 70:498-505.
4. Bax R., Douville K., McCormick D., Rosenberg M., Higgins J., Bowden M. Microbicides-evaluating multiple formulations of C31G. Contraception 2002, 66:365-368.
5. Bentley M.E., Fullem A.M., Tolley E.E., Kelly C.W., Jogelkar N., Srirak N., Mwafulirwa L., Khumalo-Sakutukwa G., Celentano D.D. Acceptability of a microbicide among women and their partners in a 4-country phase I trial. Am. J. Public Health 2004, 94:1159-1164.
6. Bentley M.E., Morrow K., Fullem A., Chesney M.A., Horton S.D., Rosenberg Z., Mayer K.H. Acceptability of a novel vaginal microbicide during a safety trial among low-risk women. Fam. Plann. Perspect. 2000, 32:184-188.
7. Braun K.E., Boyer J.D., Henderson M.H., Katz D.F., Wax A. Label-free measurement of microbicidal gel thickness using low-coherence interferometry. J. Biomed. Opt. 2006, 11:20504.
8. Carballo-Dieguez A., Balan I.C., Morrow K., Rosen R., Mantell J.E., Gai F., Hoffman S., Maslankowski L., El-Sadr W., Mayer K. Acceptability of tenofovir gel as a vaginal microbicide by US male participants in a phase I clinical trial (HPTN 050). AIDS Care 2007, 19:1026-1031.
9. Coggins C., Blanchard K., Alvarez F., Brache V., Weisberg E., Kilmarx P.H., Lacarra M., Massai R., Mishell D., Salvatierra A., Witwatwongwana P., Elias C., Ellertson C. Preliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicide. Sex. Transm. Infect. 2000, 76:480-483.
10. Coly A., Gorbach P.M. Microbicide acceptability research: recent findings and evolution across phases of product development. Curr. Opin. HIV AIDS 2008, 3:581-586.
11. Darroch J.E., Frost J.J. Women's interest in vaginal microbicides. Fam. Plann. Perspect. 1999, 31:16-23.
12. Doncel G., Clark M. Preclinical evaluation of anti-HIV microbicide products: new models and biomarkers. Antiviral Res. 2010, 88:S10-S18.
13. Dumond J.B., Patterson K.B., Pecha A.L., Werner R.E., Andrews E., Damle B., Tressler R., Worsley J., Kashuba A.D. Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J. Acquir. Immune Defic. Syndr. 2009, 51:546-553.
14. Dutta S., Joglekar N., Joshi S. Experience of conducting a phase-I safety & acceptability clinical trial of a candidate vaginal microbicide & lessons learned. Indian J. Med. Res. 2008, 128:212-213.
15. El-Sadr W.M., Mayer K.H., Maslankowski L., Hoesley C., Justman J., Gai F., Mauck C., Absalon J., Morrow K., Masse B., Soto-Torres L., Kwiecien A. Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women. AIDS 2006, 20:1109-1116.
16. Elias C., Coggins C. Acceptability research on female-controlled barrier methods to prevent heterosexual transmission of HIV: where have we been? Where are we going?. J. Womens Health Gend: Based Med. 2001, 10:163-173.
17. Friend D.R., Doncel G.F. Combining prevention of HIV-1, other sexually transmitted infections and unintended pregnancies: development of dual-protection technologies. Antiviral Res. 2010, 88:S47-S54.
18. Garg S., Goldman D., Krumme M., Rohan L.C., Smoot S., Friend D.R. Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets. Antiviral Res. 2010, 88:S19-S29.
19. Geonnotti A.R., Peters J.J., Katz D.F. Erosion of microbicide formulation coating layers: effects of contact and shearing with vaginal fluid or semen. J. Pharm. Sci. 2005, 94:1705-1712.
20. Greene E., Batona G., Hallad J., Johnson S., Neema S., Tolley E.E. Acceptability and adherence of a candidate microbicide gel among high-risk women in Africa and India. Cult. Health Sex. 2010, (Published First Online 14 April 2010). 10.1080/13691051003728599.
21. Hammett T.M., Mason T.H., Joanis C.L., Foster S.E., Harmon P., Robles R.R., Finlinson H.A., Feudo R., Vining-Bethea S., Jeter G., Mayer K.H., Doherty-Iddings P., Seage G.R. Acceptability of formulations and application methods for vaginal microbicides among drug-involved women: results of product trials in three cities. Sex. Transm. Dis. 2000, 27:119-126.
22. Hammett T.M., Norton G.D., Mason T.H., Langenbahn S., Mayer K.H., Robles R.R., Feudo R., Seage G.R. Drug-involved women as potential users of vaginal microbicides for HIV and STD prevention: a three-city survey. J. Womens Health Gend: Based Med. 2000, 9:1071-1080.
23. Hardy E., de Padua K.S., Hebling E.M., Osis M.J., Zaneveld L.J. Women's preferences for vaginal antimicrobial contraceptives. V: attitudes of Brazilian women to the insertion of vaginal products. Contraception 2003, 67:391-395.
24. Hardy E., Jimenez A.L., de Padua K.S., Zaneveld L.J. Women's preferences for vaginal antimicrobial contraceptives. III. Choice of a formulation, applicator, and packaging. Contraception 1998, 58:245-249.
25. Henderson M.H., Couchman G.M., Walmer D.K., Peters J.J., Owen D.H., Brown M.A., Lavine M.L., Katz D.F. Optical imaging and analysis of human vaginal coating by drug delivery gels. Contraception 2007, 75:142-151.
26. Hendrix C.W. Pharmacokinetic assessment of adherence. Microbicides 2010 Conference 2010, Abstract 12.
27. Hendrix C.W., Cao Y.J., Fuchs E.J. Topical microbicides to prevent HIV: clinical drug development challenges. Annu. Rev. Pharmacol. 2009, 49:349-375.
28. Hendrix C.W., Fuchs E.J., Macura K.J., Lee L.A., Parsons T.L., Bakshi R.P., Khan W.A., Guidos A., Leal J.P., Wahl R. Quantitative imaging and sigmoidoscopy to assess distribution of rectal microbicide surrogates. Clin. Pharmacol. Ther. 2008, 83:97-105.
29. Hladik F., Doncel G.F. Preventing mucosal HIV transmission with topical microbicides - challenges and opportunities. Antiviral Res. 2010, 88:S3-S9.
30. Jones H.E., Chaikummao S., van de Wijgert J.H., Friedland B.A., Manopaiboon C., Witwatwongwana P., Wankrairot M., Chantharojwong N., Kilmarx P.H. Acceptability of a Carrageenan-based candidate vaginal microbicide and matching placebo: findings from a phase II safety trial among women in Chiang Rai, Thailand. J. Womens Health 2009, 18:1003-1010.
31. Kamali A., Byomire H., Muwonge C., Bakobaki J., Rutterford C., Okong P., Profy A., Byaruhanga R., Namukwaya S., McCormack S., Grosskurth H., Nunn A.J., Lacey C.J. A randomised placebo-controlled safety and acceptability trial of PRO 2000 vaginal microbicide gel in sexually active women in Uganda. Sex. Transm. Infect. 2010, 86:222-226.
32. Koo H.P., Woodsong C., Dalberth B.T., Viswanathan M., Simons-Rudolph A. Context of acceptability of topical microbicides: sexual relationships. J. Soc. Issues 2005, 61:67-93.
33. Lai B.E., Xie Y.Q., Lavine M.L., Szeri A.J., Owen D.H., Katz D.F. Dilution of microbicide gels with vaginal fluid and semen simulants: effect on rheological properties and coating flow. J. Pharm. Sci. 2008, 97:1030-1038.
34. Liu A., Vittinghoff E., Gandhi M., Huang Y., Chillag K., Wiegand R., Anderson P., Grant R., Greenblatt R., Buchbinder S. Validating measures of tenofovir drug exposure in US pre-exposure prophylaxis trial. 17th CROI 2010, Abstract 86.
35. Louissaint N., Nimmagadda S., Bakshi R.P., Anderson J., Fuchs E.J., King K., Macura K., Hendrix C.W. Vaginal distribution of cell-free and cell-associated HIV surrogates following simulated intercourse. Microbicides 2010 2010, Abstract 211.
36. Malcolm R.K., Edwards K.L., Kiser P., Romano J., Smith T. Advances in microbicide vaginal rings. Antiviral Res. 2010, 88:S30-S39.
37. Mantell J.E., Myer L., Carballo-Dieguez A., Stein Z., Ramjee G., Morar N.S., Harrison P.F. Microbicide acceptability research: current approaches and future directions. Soc. Sci. Med. 2005, 60:319-330.
38. Mason T.H., Foster S.E., Finlinson H.A., Morrow K., Rosen R., Vining S., Joanis C.L., Hammett T.M., Seage G.R. Perspectives related to the potential use of vaginal microbicides among drug-involved women: focus groups in three cities in the United States and Puerto Rico. AIDS Behav. 2003, 7:339-351.
39. Mauck C.K., Katz D., Sandefer E.P., Nasution M.D., Henderson M., Digenis G.A., Su I., Page R., Barnhart K. Vaginal distribution of Replens and K-Y Jelly using three imaging techniques. Contraception 2008, 77:195-204.
40. Mauck C.K., Weiner D.H., Ballagh S., Creinin M., Archer D.F., Schwartz J., Pymar H., Lai J.J., Callahan M. Single and multiple exposure tolerance study of cellulose sulfate gel: a phase I safety and colposcopy study. Contraception 2001, 64:383-391.
41. Mauck C.K., Weiner D.H., Ballagh S.A., Creinin M.D., Archer D.F., Schwartz J.L., Pymar H.C., Lai J.J., Rencher W.F., Callahan M.M. Single and multiple exposure tolerance study of polystyrene sulfonate gel: a phase I safety and colposcopy study. Contraception 2004, 70:77-83.
42. Mauck C.K., Weiner D.H., Creinin M.D., Barnhart K.T., Callahan M.M., Bax R. A randomized phase I vaginal safety study of three concentrations of C31G vs. extra strength gynol II. Contraception 2004, 70:233-240.
43. Montgomery C.M., Gafos M., Lees S., Morar N.S., Mweemba O., Ssali A., Stadler J., Pool R. Re-framing microbicide acceptability: findings from the MDP301 trial. Cult. Health Sex 2010, 1. (Published First Online 14 April 2010). 10.1080/13691051003736261.
44. Montgomery C.M., Lees S., Stadler J., Morar N.S., Ssali A., Mwanza B., Mntambo M., Phillip J., Watts C., Pool R. The role of partnership dynamics in determining the acceptability of condoms and microbicides. AIDS Care 2008, 20:733-740.
45. Morrow K.M. Microbicide formulations and delivery systems: behavioral perspectives. Microbicides 2008 Conference 2008, Invited keynote address.
46. Morrow K.M. Engineering an Anti-HIV Gel for User Acceptability 2009, Invited oral presentation.
47. Morrow K.M. Acceptability of different dosage forms. CONRAD Trends in Microbicide Formulations Workshop 2010, Invited oral presentation.
48. Morrow K.M., Fava J.L., Rosen R.K., Kiser P., Katz D. Linking biophysical functions to user perceptions and acceptability in preclinical product development. 1st International Symposium on Advancing Prevention Technologies for Sexual and Reproductive Health: A Strategy Symposium 2009, Poster presentation.
49. Morrow K.M., Fava J., Kiser P., Rosen R., Katz D. The link between gel properties and user perceptions: implications for rational design of microbicides. Microbicides 2010 Conference 2010, Oral presentation.
50. Morrow, K.M., Kiser, P., Fava, J., Katz, D., in preparation. Linking physicochemical properties of vaginal gel formulations with user perceptions and willingness to use.
51. Morrow K.M., Rosen R.K., Henderson M., Vargas S., Barroso C., Katz D. Co-optimizing vaginal microbicide gel acceptability and vaginal deployment. Microbicides 2008 Conference 2008, Poster presentation.
52. Morrow K.M., Rosen R., Vargas S., Barroso C., Kiser P., Katz D. User-identified vaginal gel characteristics: a qualitative exploration of perceived product efficacy. Microbicides 2010 Conference 2010, Oral presentation.
53. Morrow K.M., Fava J.L., Rosen R.K., Christensen A.L., Vargas S., Barroso C. Willingness to use microbicides varies by race/ethnicity, experience with prevention products, and partner type. Health Psychol. 2007, 26:777-786.
54. Morrow K.M., Fava J.L., Rosen R.K., Vargas S., Barroso C., Christensen A.L., Woodsong C., Severy L. Willingness to use microbicides is affected by the importance of product characteristics, use parameters, and protective properties. J. Acquir. Immune Defic. Syndr. 2007, 45:93-101.
55. Morrow K.M., Rosen R., Richter L., Emans A., Forbes A., Day J., Morar N., Maslankowski L., Profy A.T., Kelly C., Abdool Karim S.S., Mayer K.H. The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial. J. Womens Health 2003, 12:655-666.
56. Morrow K.M., Ruiz M.S. Assessing microbicide acceptability: a comprehensive and integrated approach. AIDS Behav. 2008, 12:272-283.
57. Nimmagadda S., Fuchs E.F., Cao Y., Louissaint N., Bakshi R.P., Guidos A., Menendez F., Purdy E., Lee L., King K., Hendrix C.W. Autologous lymphocytes and HIV-sized particles in autologous seminal plasma penetrate colonic tissue following simulated receptive anal intercourse in healthy men. 4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention 2007, Abstract WEPEA112.
58. Ramjee G., Abdool Karim S.S., Morar N., Gwamanda Z., Xulu G., Ximba T., Gouws E. Acceptability of a vaginal microbicide among female sex workers. S. Afr. Med. J. 1999, 89:673-676.
59. Ramjee G., Morar N.S., Braunstein S., Friedland B., Jones H., van de Wijgert J. Acceptability of Carraguard, a candidate microbicide and methyl cellulose placebo vaginal gels among HIV-positive women and men in Durban, South Africa. AIDS Res. Ther. 2007, 4:20.
60. Reiff M., Wade C., Chao M.T., Kronenberg F., Cushman L.F. Health practices and vaginal microbicide acceptability among urban black women. J. Womens Health 2008, 17:1345-1351.
61. Rosen R.K., Morrow K.M., Carballo-Dieguez A., Mantell J.E., Hoffman S., Gai F., Maslankowski L., El-Sadr W.M., Mayer K.H. Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study. J. Womens Health 2008, 17:383-392.
62. Rupp R.E., Rosenthal S.L. Vaginal microbicides and teenagers. Curr. Opin. Obstet. Gynecol. 2003, 15:371-375.
63. Schwartz J.L., Mauck C., Lai J.J., Creinin M.D., Brache V., Ballagh S.A., Weiner D.H., Hillier S.L., Fichorova R.N., Callahan M. Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind phase I safety study. Contraception 2006, 74:133-140.
64. Severy L.J., Newcomer S. Critical issues in contraceptive and STI acceptability research. J. Soc. Issues 2005, 61:45-65.
65. Severy L.J., Tolley E., Woodsong C., Guest G. A framework for examining the sustained acceptability of microbicides. AIDS Behav. 2005, 9:121-131.
66. Szeri A.J., Park S.C., Verguet S., Weiss A., Katz D.F. A model of transluminal flow of an anti-HIV microbicide vehicle: combined elastic squeezing and gravitational sliding. Phys. Fluids 2008, 20:83101-83110.
67. Talameh J.A., Rezk N.L., Kashuba A.D. Quantifying the HIV-1 integrase inhibitor raltegravir in female genital tract secretions using high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2010, 878:92-96.
68. Tanner A., Zimet G., Fortenberry J.D., Reece M., Graham C., Murray M. Young women's use of a vaginal microbicide surrogate: the role of individual and contextual factors in acceptability and sexual pleasure. J. Sex Res. 2009, 46:15-23.
69. Tanner A.E. Perceptions of acceptability and utility of microbicides in Ghana, West Africa: a qualitative, exploratory study. Sahara J. 2008, 5:11-18.
70. Tolley E.E., Eng E., Kohli R., Bentley M.E., Mehendale S., Bunce A., Severy L.J. Examining the context of microbicide acceptability among married women and men in India. Cult. Health Sex. 2006, 8:351-369.
71. Tolley E.E., Harrison P.F., Goetghebeur E., Morrow K., Pool R., Taylor D., Tillman S.N., van der Straten A. Adherence and its measurement in phase 2/3 microbicide trials. AIDS Behav. 2009, (Published first Online 19 November 2009). 10.1007/s10461-009-9635-x.
72. Trottier S., Omar R.F., Desormeaux A., Drouin J., Gagnon M.T., Vezina F., Guilbert E., Masse B., Bergeron M.G. Safety, tolerance and acceptability of the invisible condom and its vaginal applicator in healthy women and their male sexual partners. Contraception 2007, 76:117-125.
73. Turner A.N., Van Damme K., Jamieson D.J., Khan M.R., Pettifor A.E., Swezey T.A., Bell A.J., Newman D.R., Penman-Aguilar A., Raharinivo M.S., Randrianasolo B., Ramiandrisoa F.N., Behets F.M. Predictors of adherent use of diaphragms and microbicide gel in a four-arm, randomized pilot study among female sex workers in Madagascar. Sex Transm. Dis. 2009, 36:249-257.
74. Vandebosch A., Goetghebeur E., Ramjee G., Alary M., Ettiegne-Traore V., Chandeying V., Van Damme L. Acceptability of COL-1492, a vaginal gel, among sex workers in one Asian and three African cities. Sex. Trans. Infect. 2004, 80:241-243.
75. Wang Y., Liao S.S., Weeks M.R., Jiang J.M., Abbott M., Zhou Y.J., He B., Liu W., Mosack K.E. Acceptability of hypothetical microbicides among women in sex establishments in rural areas in Southern China. Sex Transm. Dis. 2008, 35:102-110.
76. Weeks M.R., Mosack K.E., Abbott M., Sylla L.N., Valdes B., Prince M. Microbicide acceptability among high-risk urban U.S. women: experiences and perceptions of sexually transmitted HIV prevention. Sex. Transm. Dis. 2004, 31:682-690.
77. Whaley K.J., Hanes J., Shattock R., Cone R.A., Friend D.R. Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles and vaccines. Antiviral Res. 2010, 88:S55-S66.
78. Woodsong C. Covert use of topical microbicides: implications for acceptability and use. Int. Fam. Plan. Perspect. 2004, 30:94-98.
79. Zubowicz E.A., Oakes J.K., Short M.B., Perfect M.M., Succop P.S., Rosenthal S.L. Adolescents' descriptions of the physical characteristics of microbicide surrogates and experiences of use. J. Womens Health 2006, 15:952-961.